CoChat

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis

Open access
Wang, Sheng-Min, Kim, Nak-Young, Na, Hae-Ran, Lim, Hyun Kook, Woo, Young Sup, Pae, Chi-Un, Bahk, Won-Myong · 2021 · Clinical Psychopharmacology and Neuroscience
Cited by 52

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Objective: We performed a meta-analysis of randomized double-blinded placebo controlled trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major depressive disorder (MDD) including treatment resistant depression (TRD) and major depression with suicide ideation (MDSI).Methods: Mean change in total scores on Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to different time-points were our primary outcome measure.Secondary efficacy measures included rate of remission of depression and resolution of suicidality.Results: Eight DB-RCTs (seven published and one un-published) covering 1,488 patients with MDD were included.Esketamine more significantly improved MADRS total scores than placebo starting from 2-4 hours after the first administration (standardized mean difference, -0.41 [95% CI, -0.58 to -0.25], p < 0.00001), and this superiority maintained until end of double-blinded period (28 days).Sub-group analysis showed that superior antidepressant effects of esketamine over placebo in TRD and MDSI was observed from 2-4 hours, which was maintained until 28 days.Resolution of suicide in MDSI was also greater for esketamine than for placebo at 2-4 hours (OR of 2.04, 95% CIs, 1.37 to 3.05, p = 0.0005), but two groups did not statistically differ at 24 hours and day 28.Total adverse events (AEs), and other common AEs including dissociation, blood pressure increment, nausea, vertigo, dysgeusia, dizziness, and somnolence were more frequent in esketamine than in placebo group.Conclusion: Esketamine showed rapid antidepressant effects in patients with MDD, including TRD and MDSI.The study also suggested that esketamine might be associated with rapid anti-suicidal effects for patients with MDSI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.9758/cpn.2021.19.2.341

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 52

Metadata

Authors
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M.
Venue
Clinical Psychopharmacology and Neuroscience
Published
2021-05-31
Volume
19
Issue
2
Pages
341-354
ISSN
  • 1738-1088 (ISSN-L)
  • 2093-4327
OpenAlex
W3156926718
Cited by
52
References
20
FWCI
1.40
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis. https://app.cochat.ai/papers/10.9758/cpn.2021.19.2.341
The paper
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021). Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis. Clinical Psychopharmacology and Neuroscience. https://doi.org/10.9758/cpn.2021.19.2.341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.